Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amarin Corp. PLC

Latest From Amarin Corp. PLC

Hikma’s Vascepa Generic Approved But Launch Still A Mystery

Hikma has eyes on launching a generic of Amarin’s Vascepa in the US following FDA approval and a favorable patent ruling at the district level in March. However, with a swift appeal filed by the originator in the works, the Jordanian firm is yet to pull the trigger.

Generic Drugs Launches

Stockwatch: J&J Earnings Show Benefits Of Diversity In Coronavirus

Amarin and J&J opened the first-quarter 2020 earnings season. Amarin’s financial report was a mere whisper compared with J&J’s sonic boom of better-than-expected Q1 financials. Nonetheless, J&J’s reduced guidance and divisional effects will echo through the sector and the year.

Sales & Earnings Strategy

Amarin’s Q1 Vascepa Sales Exceed Expectations, But Uncertainties Remain

First quarter revenue of $150m beat analyst consensus of $129m, but investors remain wary of Amarin’s ability to overturn its recent Vascepa patent defeat and execute a favorable European strategy.

Business Strategies Legal Issues

Stockwatch: Beware The Biotech Folly Of Self-Commercialization

If the lengthy litigation history is any guide, Amgen regretted licensing its first product to a big pharma partner, probably because the product was so successful. For most first products, however, a big pharmaceutical collaboration can bring many benefits but the converse – self-commercialization of the first product – has far fewer positive historical connotations.

Business Strategies Commercial
See All

Company Information